HighVista Strategies LLC Acquires Shares of 15,728 Kymera Therapeutics, Inc. $KYMR

HighVista Strategies LLC bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 15,728 shares of the company’s stock, valued at approximately $890,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its position in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after purchasing an additional 770 shares in the last quarter. Bessemer Group Inc. raised its holdings in Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares in the last quarter. Osaic Holdings Inc. lifted its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the period. Raymond James Financial Inc. purchased a new position in Kymera Therapeutics during the second quarter valued at $73,000. Finally, US Bancorp DE boosted its holdings in shares of Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after buying an additional 166 shares in the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 4,895 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total transaction of $417,543.50. Following the sale, the chief financial officer directly owned 232,588 shares in the company, valued at approximately $19,839,756.40. This trade represents a 2.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jared Gollob sold 4,895 shares of Kymera Therapeutics stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total value of $417,543.50. Following the completion of the sale, the insider directly owned 117,134 shares of the company’s stock, valued at approximately $9,991,530.20. The trade was a 4.01% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 196,561 shares of company stock worth $17,097,428. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $79.60 on Tuesday. The firm has a market cap of $6.50 billion, a P/E ratio of -21.63 and a beta of 2.20. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The firm has a 50-day simple moving average of $79.36 and a two-hundred day simple moving average of $68.77.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.88) EPS. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KYMR. Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a research note on Monday. They issued a “buy” rating and a $110.00 price target for the company. JPMorgan Chase & Co. upped their price objective on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. UBS Group raised their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Truist Financial boosted their price target on Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Piper Sandler upped their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.